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Objectives: In human medicine, genome wide association studies have identified 25 
genetic variants in uromodulin (UMOD), which have been associated with blood 26 
pressure (BP) and renal function. Given the homology of UMOD between 27 
mammalian species, the goal of this study was to evaluate the association of 28 
currently annotated single nucleotide polymorphisms (SNPs) at the feline UMOD 29 
locus with both renal function and BP. 30 
 31 
Methods: Cats aged 14 years with systolic blood pressure (SBP) and renal 32 
function measures, and DNA samples were retrospectively selected for analysis. 33 
SNPs in the feline UMOD gene were identified, and association between UMOD 34 
SNPs and renal function (assessed by plasma creatinine concentration), and 35 
systolic blood pressure (SBP) as continuous variables were explored. Longitudinal 36 
data was used to determine associations between genotype and the dichotomous 37 
diagnoses of chronic kidney disease (CKD) and systemic hypertension.  38 
 39 
Results: Eight intronic SNPs, one 1372 base-pairs up-stream from UMOD and two 40 
exonic SNPs were evaluated in 227 cats with renal and BP data. An analysis of 188 41 
cats (where BP modifying therapy was not used) found four SNPs (p<0.01) to be 42 
significantly associated with SBP (g.9879T>C, g.9858T>C, g.9764A>C, g.8539A>C) 43 
although all were in linkage disequilibrium (LD). No significant associations were 44 
identified between SNPs and renal function or CKD. 45 
 46 
Clinical Significance: The results of this pilot study suggest that genetic variation 47 
in UMOD might influence BP in cats, similar to findings in humans and provides 48 
potential insights into the pathophysiology of hypertension in this species. The 49 
pathophysiology of this association is incompletely understood but is 50 
hypothesized to relate to sodium and water homeostasis involving the apical Na+ 51 
K+ 2Cl- cotransporter in the thick ascending limb of the loop of Henle.  52 
 53 
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 55 
Introduction: 56 
Uromodulin, otherwise known as Tamm-Horsfall protein, is a 57 
glycosylphosphatidylinositol-anchored protein that is expressed on the luminal 58 
surface of renal tubular cells of the thick ascending limb (TAL) of the loop of Henle 59 
(Vyletal et al. 2010). From this location, yet to be identified proteases release 60 
uromodulin into the urine, where it represents one of the most abundant urinary 61 
proteins in all mammalian species, and forms high molecular weight polymers 62 
(Vyletal et al. 2010). Despite uromodulin being identified in the 1950s its 63 
physiological function is still incompletely characterised. Nevertheless, 64 
uromodulin has been proposed to play an important role in the formation and 65 
trafficking of apical membrane-targeted cargo vesicles. The complex gel-like 66 
filamentous structure that it forms on the apical surface of the TAL is believed to 67 
provide a barrier to water permeability in that region and simultaneously regulate 68 
ion transportation. It has also been hypothesised that uromodulin is a receptor for 69 
binding of certain ligands which may link uromodulin to cell surface events and 70 
that localisation to cilia may indicate that uromodulin plays a role in 71 
mechanosensitisation to urinary flow and therefore intracellular signaling 72 
pathways. Within urine, it has been suggested that uromodulin maintains its gel-73 
like properties retarding the passive passage of positively-charged electrolytes 74 
such as sodium and potassium through the TAL whilst facilitating active 75 
absorptive mechanisms. In the distal tubule, it has been suggested that 76 
uromodulin may bind pathogenic bacterial strains helping to prevent urinary tract 77 
infections and in a similar manner may also act as an inhibitor of urinary stone 78 
formation (Vyletal et al. 2010, Rampoldi et al. 2011). 79 
 80 
In feline medicine, similar to other mammalian species, uromodulin has been 81 
localised to the TAL of loop of Henle (Brandt et al. 2012). Urinary uromodulin has 82 
predominantly been explored in relation to struvite and calcium oxalate calculus 83 
formation (Rhodes et al. 1993, Buffington et al. 1994, Matsumoto & Funaba 2008, 84 
Lulich et al. 2012). More recently, differential expressions of urinary proteins 85 
including uromodulin were identified in the urine of cats with chronic kidney 86 
disease (CKD) by two-dimensional gel electrophoresis (Ferlizza et al. 2015). 87 
 88 
In humans, urinary uromodulin concentrations decline with a variety of renal 89 
diseases (Thornley et al. 1985, Torffvit et al. 1998, Kottgen et al. 2010, Lhotta 90 
2010, Prajczer et al. 2010). Mutations in the UMOD gene encoding for uromodulin 91 
have been identified and associated with a series of conditions collectively 92 
referred to as uromodulin-associated kidney disease (UAKD)(Rampoldi et al. 93 
2011, Eckardt et al. 2015). UAKD represent autosomal dominant disorders for 94 
which over 50 mutations have been identified and that are characterised by 95 
tubulointerstitial fibrosis, hyperuricaemia, development of renal cysts at the 96 
corticomedullary junction and loss of urine concentrating ability (Bleyer et al. 97 
2011, Eckardt et al. 2015). More recently, interest in genetic variation within the 98 
UMOD gene has extended beyond monogenic conditions. Genetic variations 99 
within UMOD have been identified, from genome-wide association studies 100 
(GWAS) and meta-analyses, to be associated with estimated glomerular filtration 101 
rate (eGFR), CKD, incident CKD, decline in renal function and end-stage renal 102 
disease (Kottgen et al. 2009, 2010, Gudbjartsson et al. 2010, Boger et al. 2011, 103 
Reznichenko et al. 2012, Gorski et al. 2015). Genetic variants in UMOD have also 104 
been associated with hypertension (HT) using both GWAS and candidate gene 105 
approaches (Padmanabhan et al. 2014, Cabrera et al. 2015). An extreme case–106 
control GWAS study of European individuals identified that the minor allele for 107 
SNP rs13333226 was protective against HT (Padmanabhan et al. 2010). When the 108 
association of rs13333226 with continuous blood pressure measurement was 109 
evaluated, the minor allele was found to be significantly associated with a 0·5 110 
mmHg lower systolic blood pressure (SBP) and 0·3 mmHg lower diastolic blood 111 
pressure, results of which are concordant with the odds of HT (Padmanabhan et 112 
al. 2010). This discovery study was subsequently validated in a large-scale case–113 
control study in which this protective effect was replicated (Padmanabhan et al. 114 
2010). Studies by Han et al. and Iwai et al. evaluated single nucleotide 115 
polymorphisms (SNPs) in UMOD as a candidate gene in Chinese and Japanese 116 
populations, respectively (Iwai et al. 2006, Han et al. 2012). 117 
 118 
Both CKD and systemic HT are common conditions in the ageing feline population, 119 
which may be considered as complex disease traits likely influenced by both 120 
genetic and environmental factors (Lulich et al. 1992, Syme et al. 2002, 2006, 121 
Jepson 2011, Marino et al. 2014). To date there have been no studies that have 122 
evaluated potential genetic associations in these conditions. Indeed the concept of 123 
investigating genetic associations in complex disease traits in cats is novel. The 124 
aim of this study was to build on the known homology and conservation of the 125 
UMOD gene across mammalian species, and using publically-available genetic 126 
polymorphism data for the feline UMOD gene to evaluate associations between 127 
genotype and the continuous traits of renal function and SBP, and the 128 
dichotomous traits of CKD and systemic HT. Further information about the design 129 
and interpretation of genetic association studies can be found in the following 130 
review articles: Cordell & Clayton 2005, Hattersley & McCarthy 2005, Palmer & 131 
Cardon 2005, Bush & Moore 2012. 132 
 133 
Materials and Methods: 134 
Case selection:  135 
Cats included in this study were selected retrospectively from a computerised 136 
database containing clinical data for cats that had participated in a longitudinal 137 
geriatric cat monitoring programme. All cats had been evaluated at one of two first 138 
opinion clinics in (Beaumont Sainsbury Animal Hospital, Camden, London and 139 
People's Dispensary for Sick Animals, Bow, London) and at enrollment to the 140 
longitudinal programme a full history had been obtained, physical examination 141 
performed and SBP assessed as previously described using the Doppler technique 142 
(Syme et al. 2002). 143 
 144 
The collection and storage of blood samples was performed with owner consent 145 
and the protocols adhered to within this study had been approved by the Ethics 146 
and Welfare Committee at the Royal Veterinary College, London, UK. Blood 147 
samples were obtained by jugular venipuncture and collected into lithium heparin 148 
and EDTA. Samples were held on ice (4°C) for a maximum of 6 hours before 149 
centrifugation and separation. Plasma biochemical analysis (Idexx laboratories), 150 
packed cell volume and total protein evaluation were routinely performed for all 151 
cats on enrollment to the longitudinal monitoring programme. Total serum 152 
thyroxine concentration was measured in all cats in which the history (e.g. 153 
polyphagia, weight loss), physical examination findings (e.g. tachycardia, 154 
arrhythmia, poor body condition, palpable goiter), or serum biochemical findings 155 
(increased alanine transferase or alkaline phosphatase activities) raised concern 156 
for hyperthyroidism. In all cases in which the urinary bladder was palpable, a 157 
urine sample was collected by cystocentesis. For every cat enrolled in the 158 
longitudinal monitoring programme residual sample (EDTA, serum, heparinised 159 
plasma) and EDTA cell pellets mixed with a 1:1 ratio of EDTA-phosphate buffered 160 
saline were stored at −80°C, the latter to be used for genomic DNA extraction. 161 
 162 
Cats that were considered healthy on the basis of these data were offered re-163 
examination on a 6-monthly basis. Cats were diagnosed with azotaemic CKD if 164 
plasma creatinine was greater than laboratory reference interval (177 µmol/L) on 165 
two occasions a minimum of 4 weeks apart in association with inappropriate urine 166 
concentrating ability (urine specific gravity<1·035). Cats were diagnosed with 167 
systemic HT if SBP was greater than 170 mmHg on one occasion in association 168 
with hypertensive ocular target organ damage or if SBP greater than 170 mmHg 169 
on at least two occasions. 170 
 171 
Cats diagnosed with hyperthyroidism, HT and/or CKD either at enrollment or at 172 
subsequent visits in the longitudinal monitoring programme were offered 173 
standard management and re-examined every 8 weeks. At each re-examination 174 
visit clinical information was reviewed and physical examination including repeat 175 
assessment of SBP and bodyweight performed. At every other visit (i.e. every 16 176 
weeks), blood and urine samples were obtained. For cats diagnosed with 177 
hyperthyroidism this included assessment of total thyroxine and renal 178 
parameters providing euthyroidism was maintained. For cats with a diagnosis of 179 
CKD or systemic HT this included assessment of renal parameters. When urine 180 
could be obtained a full urinalysis including specific gravity, dipstick and sediment 181 
examination was performed. Urine culture was performed for patients with 182 
compatible clinical signs (stranguria, dysuria, pollakiuria, haematuria) or where 183 
there was indication on urine sediment examination (pyuria, bactiuria, 184 
haematuria) for a urinary tract infection. 185 
 186 
Cats diagnosed with CKD were provided with a commercially available renal diet 187 
free of charge and, where indicated in accordance with the IRIS guidelines, 188 
additional intestinal phosphate binder and potassium supplementation. Systemic 189 
HT was routinely treated with amlodipine besylate (0·625 to 2·5 mg/cat once a 190 
day) to a target SBP less than 160 mmHg. Hyperthyroidism was initially managed 191 
medically with the option for uni-/bi-lateral surgical thyroidectomy. Data from 192 
every cat enrolled in the longitudinal monitoring programme from every visit 193 
were collated within a searchable computerised database. Longitudinal 194 
monitoring was provided for cats for the duration of their life or until the client 195 
elected to withdraw from the study. Cats were excluded from the longitudinal 196 
monitoring programme only if significant concurrent disease precluded provision 197 
of care through the clinic, e.g. diabetes mellitus. 198 
 199 
Data from approximately 2900 cats greater than nine years old available on the 200 
computerised database were initially screened. Cats for inclusion in the current 201 
genetic association study were selected from the computerised database by 202 
identification of the first visit after they turned 14 years old, where full 203 
biochemical and SBP data were available, as well as a stored cell pellet for genomic 204 
DNA extraction. Cats were excluded if they were identified as newly-diagnosed or 205 
uncontrolled hyperthyroid at the visit of interest. Cats diagnosed with 206 
hyperthyroidism but adequate control of hyperthyroidism (total T4 10 to 45 207 
nmol/L) documented at the time of biochemical assessment were included in the 208 
study. Ultimately, all cats identified from the computerised database fulfilling the 209 
inclusion and exclusion requirements and from which genomic DNA was available 210 
were used in this study. Sample size was therefore driven by availability. In 211 
addition, when evaluating the association of genotype with SBP at enrollment, cats 212 
were excluded if they were receiving antihypertensive medication, typically 213 
amlodipine besylate, or medications that might modify BP, e.g. angiotensin 214 
receptor blocker, angiotensin converting enzyme inhibitor, beta-blocker. 215 
 216 
Data available permitted cross-sectional evaluation of the outcome variables 217 
relating to renal function (quantitative creatinine and dichotomous CKD 218 
diagnosis) and quantitative SBP at the first visit when cats were aged 14 years and 219 
also longitudinal evaluation of the development of systemic HT throughout follow-220 
up. 221 
 222 
Single nucleotide polymorphism identification:  223 
The currently reported coding sequence of UMOD was explored (Ensembl 224 
http://www.ensembl.org/Felis_catus/Info/Index; ENSFCAG00000004381. 225 
GenBank Assembly ID GCA_000181335.1, Felis_catus_6.2 ChrE3: 27156434-226 
27168778). Previously published annotated single nucleotide polymorphisms 227 
(SNPs) within either intron and exon regions of the UMOD gene were identified 228 
using a previously available genome assembly (http://genome-euro.ucsc.edu 229 
NHGRI/GTP V17e/felcat4/GenBank assembly accession: GCA_000003115.1) and 230 
a recent release of annotated feline SNPs 231 
(http://public.dobzhanskycenter.ru/Hub/hub.txt) which were mapped to the 232 
Felis_catus_6.2 genome assembly (Mullikin, Hansen et al. 2010, Tamazian, 233 
Simonov et al. 2014). Location of SNPs within the UMOD gene sequence was 234 
confirmed by blast search against the feline, canine and human nucleotide 235 
collection (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi). Polyphen 236 
(http://genetics.bwh.harvard.edu/pph2) was used to predict the impact of the 237 
amino acid substitution on the structure and function of UMOD for non-238 
synonymous SNPs within UMOD exons.  239 
 240 
Genotyping:  241 
Genomic DNA (gDNA) was extracted from buffy coat enriched packed cells using 242 
a commercially available kit (Sigma GenElute Blood Genomic DNA kit, Sigma-243 
Aldrich Company Ltd.) according to the manufacturer's instructions and 244 
subsequent spectrophotometric (Nanodrop 1000 Spectrophotometer, Thermo 245 
Scientific) quantification. gDNA was diluted with nucleic acid-free H2O (Water, 246 
Molecular Biology Reagent, Sigma-Aldrich Company Ltd) to a final concentration 247 
of 5 ng/μL for genotyping. 248 
 249 
For all evaluated SNPs, primers were designed based on the SNP locus sequence 250 
for a PCR-based competitive allele-specific PCR (KASP™) genotyping assay 251 
(KASP™, LGC Genomics) using Primerpicker [Primepicker (previously 252 
KBiosciences) LGC Genomics, KBS-1016-022 (25 mL) KASP™  Master Mix, LGC 253 
Genomics]. This produced two allele-specific oligonucleotides with unique 5′ 254 
tails and one common reverse oligonucleotide. For each genotyping assay, the 255 
allele-specific and common primers were diluted in nucleic acid-free H2O to a final 256 
concentration of 100 μM and combined as a SNP-specific assay mix (12 μL allele-257 
specific primer 1+12 μL allele-specific primer 2+30 μL common primer+46 μL 258 
dH2O). Buffer mix was prepared using KASP™ assay mix (KBS-1016-022 (25 mL) 259 
KASP™ Master Mix, LGC Genomics) [containing universal fluorescent resonance 260 
energy transfer (FRET) cassettes with the dyes FAM and VIC, high ROX™ passive 261 
reference dye, Taq polymerase and free nucleotides] and MgCl2 (50 mM) to give 262 
a final concentration of 1·8 mM. 263 
 264 
For genotyping assays, 7·5 ng of gDNA was applied per well using a 384 well 265 
format (AB Biosystems) and air-dried at 65°C for a minimum of 2 hours or 266 
overnight. A master mix was prepared by the addition of 16 μL SNP-specific assay 267 
mix and 1008 μL buffer mix with 2·5 μL added to each well before covering with 268 
optical adhesive PCR film. The following PCR cycling sequence (Tetrad PTC 225 269 
Peltier Thermocycler (previously MJ Research), BIO-RAD, Hemel Hempstead) was 270 
used for all assays: 94°C for 15 minutes, 10 cycles of 94°C for 20 seconds with 271 
touch down over 65 to 70°C for 60 seconds (reducing by 0·8°C per cycle), 26 cycles 272 
of 94°C for 20 seconds and 57°C for 60 seconds. Allelic discrimination was 273 
performed (ABI PRISM® 7900HT, Applied Biosystems, Thermo Fisher Scientific) 274 
with manual cluster detection (SDS 2.3, Applied Biosystems, Thermo Fisher 275 
Scientific). Genotyping assays were initially tested across 24 cats and assays that 276 
performed well were taken forwards for genotyping of all cats using a randomised 277 
format and including nucleic acid-free H2O (n=8) as a negative control. 278 
 279 
Statistical analysis:  280 
Summaries of the clinical data are presented in Table 1, showing the median and 281 
interquartile range (IQR) for each variable. A non-parametric Mann–Whitney U 282 
test was used to compare these clinical variables as well as the duration of follow-283 
up between normotensive and hypertensive cats and between cats diagnosed 284 
with azotaemic CKD aged 14 years and those, which were non-azotaemic aged 13 285 
years (see Tables 2 and 3). For all clinical statistical analyses P<0·05 was 286 
considered significant. 287 
 288 
Associations between quantitative and binary response variables and SNPs were 289 
performed using PLINK with either linear or logistic regression models 290 
respectively (Purcell et al. 2007). Quantitative variables were assessed for 291 
normality by visual inspection of histograms and also the Kolmogorov–Smirnov 292 
test. Due to skewness, creatinine concentration was logarithmically transformed 293 
before analysis. Genotype frequencies, minor allele frequency (MAF), Hardy–294 
Weinberg equilibrium (HWE; using the exact Hardy–Weinberg test) and linkage 295 
disequilibrium (LD) were evaluated. MAF greater than 10% was chosen to include 296 
only common variants and therefore to improve power to detect a significant 297 
association given the relatively small sample size. For quality control, summary 298 
statistics were checked for the genotype call rates per SNP and per cat, and a SNP 299 
call rate threshold of greater than 90% was used. Pairwise LD values were 300 
calculated in PLINK using data from our cohort of cats due to lack of available 301 
known feline LD reference data (unlike in human GWAS). An r2 value of >0·5 was 302 
used based on suggested threshold from PLINK of 0·5 “being necessary to declare 303 
that one SNP tags another” (Purcell et al. 2007). An additive model was used for 304 
all SNP associations, with results corresponding to a per allele unit effect. For 305 
genotyping analyses Bonferroni correction was applied to adjust for multiple 306 
testing. Based on pairwise LD the SNPs reduced to a set of five pairwise 307 
independent SNPs (Table S2) and therefore for genotyping analyses statistical 308 
significance was defined as P<0·01 (using Bonferroni correction: P=0·05/5). 309 
 310 
Associations were evaluated for the quantitative variables log-creatinine and SBP 311 
at the time of biochemical assessment aged 14 years and for the binary outcome 312 
of diagnosis of azotaemic CKD aged 14 years. Longitudinal clinical data available 313 
from computerised records for all cats were assessed in order to determine 314 
whether, during their entire period of monitoring, cats had ever been diagnosed 315 
with systemic HT. A single case–control association was then subsequently 316 
explored with the binary outcome of ever becoming hypertensive versus 317 
remaining normotensive during the available period of follow-up. For both the 318 
quantitative trait SBP and the binary outcome hypertensive/normotensive 319 
analyses, log-creatinine concentration was included as a covariate for adjustment 320 
based on potential association between renal function and likelihood of 321 
developing HT. For the quantitative variable log-creatinine and the binary 322 
outcome of diagnosis of CKD aged 14 years no covariates were included. 323 
 324 
Results: 325 
Stored cell pellets were available for 227 cats. The median age of cats was 14·4 326 
years (IQR 14·2 to 4·6 years). Of this population of cats 78·4% (n=178) were 327 
domestic shorthair, 8·8% domestic longhair (n=20) with the following breeds also 328 
represented; Burmese n=10 (4·4%), Persian n=6 (2·6%), Persian cross n=3 329 
(1·3%), with two each of the following breeds; British blue, Russian blue cross, 330 
Siamese and one each of the following breeds; American shorthair, Maine coon, 331 
occicat, Russian blue. 332 
 333 
Clinical and biochemical data for cats at recruitment to the study are provided in 334 
Table 1. Hyperthyroidism had previously been diagnosed in 19% (44/227) of cats 335 
and was documented to be well-controlled, both on the basis of clinical signs and 336 
total thyroxine measurement (n=44 median total thyroxine 22·9 nmol/L; IQR 17·1 337 
to 31·7 nmol/L). Twenty-one of the cats that had been diagnosed with 338 
hyperthyroidism had previously undergone either uni- or bi-lateral 339 
thyroidectomy and therefore were not receiving any antithyroid medication at the 340 
point of enrollment. At the time of initial assessment 33·9% (77/227) of cats had 341 
been diagnosed with azotaemic CKD. Clinical data are compared between cats 342 
diagnosed with azotaemic CKD and non-azotaemic cats at entry to the study in 343 
Table 2. As may be anticipated cats diagnosed with azotaemic CKD had 344 
significantly higher plasma creatinine concentration, lower packed cell volume 345 
and urine specific gravity. Potassium concentration was unexpectedly 346 
significantly higher in cats with azotaemic CKD (P=0·034) and, despite selection 347 
of cats from the 14th year of life, cats with azotaemic CKD at enrollment were 348 
younger (P=0·02) than non-azotaemic cats. 349 
 350 
Systemic HT had previously been diagnosed in 17% (39/227) of cats at 351 
enrollment in the study of which all were receiving amlodipine besylate therapy 352 
and 46% (18/39) of these hypertensive cats had been diagnosed with azotaemic 353 
CKD. Clinical records for all 227 cats were reviewed to determine whether 354 
systemic HT developed during their period of follow-up. The median period of 355 
follow-up for all cats from the date of sampling in their 15th year until death, 356 
euthanasia or the study end point (end of December 2014) was 850 days (399, 357 
1218 days). During this period, 81 cats were diagnosed with systemic HT and 146 358 
remained normotensive and there was no significant difference in duration of 359 
follow-up between groups (Table 3). Twenty-one cats went on to develop 360 
hyperthyroidism of which 23·8% (5/21) underwent thyroidectomy and the 361 
remainder received medical management. Clinical data at entry to the study are 362 
compared between cats that developed systemic HT and those that remained 363 
normotensive throughout follow-up (Table 3). Potassium and urine specific 364 
gravity were significantly lower (P<0·05) in cats at enrollment if they were 365 
diagnosed during follow-up with systemic HT than if they remained 366 
normotensive. 367 
 368 
Single nucleotide polymorphism identification:  369 
Eight intronic SNPs and one SNP 1372bp upstream of the feline UMOD reference 370 
sequence were identified (Table 4) using published data by Mullikin and 371 
colleagues (2010) from a previously available genome assembly (NHGRI/GTB 372 
V17e/felcat4) GenBank assembly GCA_000003115.1). KASP™ assays were 373 
designed for genotyping (Supplemental Table A)(Mullikin et al. 2010). Location 374 
within the predicted UMOD gene sequence (Supplemental data Figure 1) from the 375 
current genome assembly was confirmed by performing a nucleotide BLAST 376 
search against the feline nucleotide collection. Genotype frequencies are reported 377 
in Table 4.  378 
 379 
A further three exonic UMOD SNPs were identified using recently published data 380 
by Tamazian et al. (Table 4). Two of these SNPs (g.1381T>A and g.1664A>G) are 381 
non-synonymous and located in exon 2; one is a synonymous SNP (g.4635T>C) 382 
located in exon 5 (Fig S1). Polyphen was used to predict the impact of the amino 383 
acid substitution on the structure and function for both non-synonymous SNPs 384 
(Adzhubei et al. 2010). The two SNPs were considered as benign (g.1381T>A, 385 
p.ser74thr: score 0·009, sensitivity 0·96, specificity 0·77 and g.1664A>G, 386 
p.asp168gly: score 0·002, sensitivity 0·99, specificity 0·3). KASP™ assays were 387 
designed for all three SNPs but were successful for only two (exonic g.1381T>A 388 
and intronic g.4635T>C). Ultimately the exonic non-synonymous SNP g.1381T>A 389 
which was considered benign using Polyphen modelling did not have a MAF 390 
greater than 10% and therefore was not evaluated within association studies. 391 
Genotyping frequency data are presented in Table 4. 392 
 393 
One reported SNP (g.1664A>G) failed to genotype in any of the cats and was 394 
excluded from further analysis with uncertainty whether this represented primer 395 
failure or that this was not a true SNP. Overall genotype rate was 0·967561 and all 396 
SNPs demonstrated a genotype failure rate less than 10%. Forty-eight cats failed 397 
to genotype in ≥1 SNP (28 cats failed in one SNP, 10 cats failed two SNP, four cats 398 
failed three SNPs, four cats failed four SNPs and one cat failed in five SNPs). 399 
However, given the relatively small sample size all cats were retained in the study. 400 
Evaluating genotype data from all cats, seven SNPs had a MAF greater than 10% 401 
(Table 4) and were used for further evaluation, restricting to analysis of common 402 
variants as appropriate for this sample size. HWE data are presented in Table 4. 403 
LD pairwise comparison identified that there were five independent SNPs (Table 404 
S2; g.4635T>C, g.1381T>A, g.6902C>T, g.3390G>A and 5′ upstream 1372 bp 405 
G>A). 406 
 407 
Association between UMOD genotype and renal function 408 
Seven SNPs with MAF greater than 10% (Table 4) were analysed for associations 409 
with renal function using the quantitative trait log-creatinine and the binary 410 
outcome of being diagnosed with azotaemic CKD in 15th year of life or being non-411 
azotaemic. We observed no significant association between SNPs and log-412 
creatinine (Table S3). Similarly there were no SNPs significantly associated with 413 
the diagnosis of CKD as a binary variable (all had P>0·01; Table S4). 414 
 415 
Association between UMOD genotype, systolic blood pressure and systemic 416 
hypertension 417 
After exclusion of cats that were receiving antihypertensive or BP-modifying 418 
medication at the time of enrollment, 188 cats were available for evaluation of 419 
association between genotype and SBP as a continuous variable (Table S6). Seven 420 
SNPs demonstrated MAF greater than 10% (Table S5) and were included in the 421 
analysis (Table S6). Four SNPs were significantly associated (P<0·01; Table 5) 422 
with SBP as a quantitative variable, adjusted for plasma creatinine as a covariate 423 
(Table S6) but all four were in LD, suggesting one overall distinct association 424 
signal. 425 
 426 
Clinical record data for all 227 cats were reviewed in order to categorise cats as 427 
normotensive or hypertensive during their period of follow-up at the clinics 428 
(Table 3). No SNPs with MAF greater than 10% were significantly associated with 429 
the hypertensive state (all had P>0·01; Table S7). 430 
 431 
Discussion: 432 
This study demonstrates that genetic variants in UMOD are significantly and 433 
positively associated with SBP but not with systemic HT as a specific outcome. 434 
This finding is comparable to the associations that have been made to date in 435 
human medicine (Iwai et al. 2006, Padmanabhan et al. 2010, Han et al. 2012). The 436 
SNP identified in human medicine (rs13333226), located within the promotor 437 
region of UMOD has been associated with a lower risk of HT (Padmanabhan et al. 438 
2010). However, in our current study, SNPs that reached statistical significance 439 
were associated positively with SBP. The four SNPs that demonstrated association 440 
with SBP were not independent and shown to be in LD. There is relatively little 441 
known about LD in cats and the values generated for the current study were 442 
inferred from this population alone using an LD r2 value that was lower than 443 
typically applied to human studies (Alhaddad et al. 2013). The SNPs where 444 
significant association was identified were intronic. Therefore any effect from 445 
these SNPs will not be the result of structural change in the uromodulin amino 446 
acid sequence but could reflect, for example, alteration in splicing or post-447 
translational modifications (Shastry 2009). The overall effect of SNPs significantly 448 
associated with SBP in this study appears proportionally large compared to effects 449 
identified in human medicine. It can be hypothesised that potentially the cat may 450 
be different from the human in terms of the complexity of SBP as a trait giving rise 451 
to this greater effect. However, further work is required to validate the SNPs 452 
identified in independent cohorts of cats in order to establish this association. 453 
 454 
The mechanism by which genetic variation in UMOD is associated with control of 455 
BP is incompletely understood. However, studies suggest that this may relate to 456 
alteration in permeability of the TAL of the loop of Henle to water and modulation 457 
of sodium handling by the apical Na+K+2Cl− cotransporter (NKCC2). Recent 458 
studies have used uromodulin knockout mice to further elucidate the role played 459 
by uromodulin. Uromodulin knockout (UMOD−/−) mice demonstrate no 460 
abnormalities in electrolyte balance but do show significantly reduced creatinine 461 
clearance and impaired urine-concentrating ability and decreased NKCC2 activity 462 
(Bachmann et al. 2005, Mutig et al. 2011). Transfection of TAL cells with 463 
uromodulin resulted in increased concentration of phosphorylated NKCC2 and 464 
increased intracellular chloride concentration indicating that uromodulin plays an 465 
important facilitating role in absorption of sodium and activity of the NKCC2 466 
cotransporters within the TAL (Mutig et al. 2011, Trudu et al. 2013). In addition, 467 
knockout studies suggest that uromodulin may regulate expression of other 468 
channels including, amongst others, the renal outer medullary potassium channel 469 
(ROMK2) (Bachmann et al. 2005, Renigunta et al. 2011). This is a potentially 470 
interesting concept given that cats with systemic HT have previously been shown 471 
to have significantly lower plasma potassium concentrations than their 472 
normotensive counterparts, a finding which was also seen in the present study 473 
(Syme et al. 2002, Bijsmans et al. 2015). 474 
 475 
A study by Graham et al. has demonstrated that UMOD−/− mice have significantly 476 
lower SBP (116·6 ±0·3 mmHg) than wild-type mice (136·2 ±0·4 mmHg) and that 477 
the knockout mice show no response in terms of alteration in BP to sodium 478 
loading (Graham et al. 2014). The pressure-natriuresis curve was also shifted to 479 
the left in UMOD−/− mice (Graham et al. 2014). A further study conversely 480 
demonstrated that over-expression of uromodulin resulted in increased 481 
uromodulin excretion and increased BP (Trudu et al. 2013). 482 
 483 
TNFα has also been shown to downregulate NKCC2 expression in an autocrine 484 
manner and it has been suggested that TNFα may be a link between the intra- and 485 
extra-cellular roles of uromodulin and BP regulation (Battula et al. 2011); 486 
UMOD−/− mice showed increased urinary TNFα concentrations compared to 487 
wild-type mice (Graham et al. 2014). Cells from the TAL were isolated from wild-488 
type mice and stimulated with TNFα resulting in a reduction in NKCC2 expression, 489 
and simultaneous increase in UMOD mRNA expression (Graham et al. 2014). This 490 
work suggests that uromodulin modulates the effect of TNFα on NKCC2 491 
expression and hence may affect BP regulation. However, further work is required 492 
to exactly characterise this molecular mechanism. To date, although studies report 493 
the measurement of uromodulin in cats using experimental collection of large 494 
volumes of urine, it has not been possible to validate a human-based ELISA system 495 
for urine uromodulin quantification (Lulich et al. 2012). Nevertheless, this would 496 
be an interesting avenue for further study in order to explore the relationship 497 
between genetic variation and uromodulin expression in cats. 498 
 499 
In contrast to data from human medicine, no association could be identified 500 
between genetic variants in UMOD and plasma creatinine as a marker of renal 501 
function or the outcome of a diagnosis of CKD. In human medicine, a significant 502 
association has been identified between UMOD variant rs12917707 and CKD 503 
defined as an estimated GFR (eGFRcreat) using creatinine (eGFRcreat) of <60 504 
mL/kg/minute/1·73 m2 in both discovery and replication groups (Kottgen et al. 505 
2009, Psaty et al. 2009). However, it is important to note that within the meta-506 
analysis, even when combining six risk alleles, only 0·7% of the variance in 507 
eGFRcreat could be explained (Kottgen et al. 2009). The association between 508 
UMOD variants and renal function have been replicated in an independent 509 
population in which the UMOD tag-variant rs4293393 was significantly associated 510 
with both CKD and serum creatinine concentration (The International HapMap C 511 
2005, Gudbjartsson et al. 2010). UMOD variants (rs12917707 and rs4293393) 512 
have also been significantly associated with the risk of incident CKD in humans 513 
and more recently they have been associated with development of end-stage renal 514 
disease in humans (Kottgen et al. 2009, 2010, Boger et al. 2011). 515 
 516 
It can be hypothesised that, if the effect of genetic association between UMOD and 517 
renal function is smaller than that for BP, lack of association with renal function 518 
in the current study may reflect the small sample size. In the current study every 519 
available cat meeting the study criteria was included. Given this available sample 520 
size, we have performed power calculations retrospectively (Purcell et al. 2003) 521 
to estimate the expected power achievable from an analysis of N=227 cats for 522 
detecting effects of associated SNPs with MAF≥10%. For BP traits, which are 523 
known to only have small effects for each SNP individually in humans, the sample 524 
of 227 cats may only have ~20% power. For renal trait associations, for which we 525 
anticipate higher power, as human studies indicate larger effect sizes, the sample 526 
of 227 cats may have ~40% power. These calculations include estimates and 527 
assumptions for heritability and LD structure known from human genetics. 528 
However, with no prior GWAS of BP and renal traits in cats, the accuracy of these 529 
estimates is unknown. Analysis of this pilot study data and the quality control 530 
diagnostics performed suggest that there may be stronger LD structure within 531 
cats, compared to humans. If this is the case, the power could actually be higher 532 
than has been estimated, which may explain the successful identification of 533 
associations among UMOD SNPs and SBP. Equally the small sample size means 534 
that there is insufficient evidence to conclude absence of a significant association 535 
between UMOD variants and HT or renal traits from this study. 536 
 537 
Although a range of intronic and exonic SNPs were evaluated in this study only 5 538 
out of 11 were ultimately identified to be independent, and therefore there were 539 
only a limited number of distinct signals that could be analysed for these data. 540 
Furthermore, in the current study, plasma creatinine was used as a marker of GFR 541 
whilst in comparable human studies estimated GFR based on either creatinine or 542 
cystatin C were commonly used. Creatinine is recognised to be a less precise 543 
marker of GFR particularly in the early stages of CKD than estimated GFR 544 
calculations. It is therefore possible that as yet undiscovered SNPs in the feline 545 
UMOD gene may be associated with renal function or that an association may be 546 
identified if more precise markers of renal function are employed. 547 
 548 
A further limitation of the current study was inclusion of cats which either had a 549 
prior diagnosis of hyperthyroidism and had undergone surgical thyroidectomy or 550 
medical management, or which were identified to become hyperthyroid during 551 
follow-up. Hyperthyroidism had previously been diagnosed in 19% of cats at 552 
enrollment to this study. From the feline literature, approximately 10% of cats are 553 
diagnosed with systemic HT at diagnosis of hyperthyroidism with approximately 554 
20% demonstrating HT after treatment and return to euthyroidism (Morrow et al. 555 
2009, Williams et al. 2010). In human patients and experimental studies, 556 
hyperthyroidism results in a reduction in systemic vascular resistance that is 557 
offset by an increase in cardiac output, thus the net effect of hyperthyroidism is 558 
towards a small decline in blood pressure (Syme 2007). The underlying 559 
pathophysiology of systemic HT documented in cats with hyperthyroidism 560 
remains to be determined, but may relate to the decline in renal function identified 561 
with return to euthyroidism (Williams et al. 2010, 2013). If this is the case then it 562 
remains possible that genetic variants, such as those identified in uromodulin, 563 
could be common to all cats and still play a predisposing role in the development 564 
of systemic HT. Every attempt was made to ensure that cats were truly euthyroid 565 
at the point of inclusion aged 14 years. It is therefore hoped that any effect of a 566 
prior diagnosis of hyperthyroidism on both SBP and renal function as assessed by 567 
plasma creatinine will have been minimised at this time. The association analysis 568 
for SBP was repeated excluding cats that were receiving medical therapy for their 569 
hyperthyroidism without documenting any change in association results (data not 570 
presented) implying that inclusion of these cats did not adversely affect the 571 
results. However, despite careful longitudinal monitoring, it is possible that either 572 
failure to make an early diagnosis of hyperthyroidism or medical management of 573 
hyperthyroidism in those patients where a diagnosis was made, could have 574 
impacted on our ability to define cats as hypertensive during follow-up. 575 
 576 
Further novel SNP discovery is warranted and continued exploration with novel 577 
renal markers, e.g. symmetric dimethylarginine. In particular, the SNP 578 
associations in human medicine both with renal function and BP have been 579 
located within the promoter region for the UMOD gene (Kottgen et al. 2009, 580 
Padmanabhan et al. 2010). Focusing on SNPs within the promoter region of the 581 
feline UMOD gene may be of greatest benefit. A further aspect of association that 582 
was not performed in the current study on cats but which has been evaluated in 583 
human medicine is the association between genetic variants and progression of 584 
renal disease (Gorski et al. 2015). 585 
 586 
In conclusion, this exploratory pilot study suggests that there may be similarities 587 
between humans and cats in the underlying mechanisms of BP regulation and the 588 
role that genetic variants in UMOD play in modifying BP. Further work is required 589 
to replicate and validate these preliminary findings in a separate cohort of cats 590 
and to explore the relationship between uromodulin excretion and UMOD genetic 591 
variation in cats. 592 
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Table 1: Clinicopathological data for cats at enrollment to the study 610 
 611 
 612 
Clinical parameter Median (25th, 75th) N 
Age (years) 
 
Urea (mmol/L) 
 
Creatinine (µmol/L) 
 
 
Phosphorus (mmol/L) 
 
USG 
 
UP/C 
 
Total thyroxine (nmol/L) 
 
SBP (mmHg) 
 
Weight (kg) 
 
Diagnosed with azotaemic CKD 
at enrollment 
 
Previous diagnosis of systemic 
hypertension at enrollment 
 
Proportion of cats with systemic 
hypertension diagnosed with 
azotaemic CKD 
14·4 (14·2, 14·6) 
 
12·0 (9·7, 15·9) 
 
154·3 (127·6, 192·7);  
range 63·8 to 550·8 
 
1·28 (1·10, 1·48) 
 
1·030 (1·020, 1·042) 
 
0·15 (0·00, 2·99) 
 
22·3 (16·5, 28·2) 
 
140 (127·2, 155·6) 
 
4·06 (3·42, 4·65) 
 
- 
 
 
- 
 
 
- 
 
227 
 
227 
 
227 
 
 
227 
 
191 
 
70 
 
141 
 
227 
 
219 
 
52/227 
22·9% 
 
39/227 
17% 
 
18/39 
46% 
 613 
  614 
Table 2: Comparison of clinical parameters between cats diagnosed with 615 
azotaemic CKD at enrollment versus non-azotaemic cats 616 
 617 
 618 
 619 
 620 
Variable 
(units) 
Non-
azotaemic 
cats 
n 
Cats 
diagnosed 
with 
azotaemic 
CKD 
n Significance (P) 
 
Age at visit 
during 15th year 
14·4 (14·2, 14·6) 150 14·3 (14·1, 14·6) 77 0·02 
Creatinine 
(µmol/L) 
137·0 (116·7, 
155·3) 
150 215·0 (190·0, 
251·0) 
77 <0·0001 
Phosphorus 
(mmol/L) 
1·27 (1·09, 1·44) 150 1·31 (1·16, 1·61) 77 0·127 
Potassium 
(mmol/L) 
3·90 (3·70, 4·20) 150 4·07 (3·72, 4·30) 77 0·034 
Weight (kg) 4·01 (3·42, 4·64) 146 4·10 (3·48, 4·70) 73 0·502 
Systolic blood 
pressure 
(mmHg) 
138 (126·0, 
156·0) 
150 143 (128·5, 156) 77 0·257 
Packed cell 
volume (%) 
37·0 (34·0, 40·0) 149 34·5 (30·0, 38·0) 76 0·005 
Urine specific 
gravity 
1·036 (1·028, 
1·050) 
120 1·020 (1·016, 
1·024) 
71 <0·0001 
Urine protein to 
creatinine ratio 
0·16 (0·12, 0·29) 38 0·14 (0·09, 0·26) 32 0·328 
Duration of 
follow-up (days) 
899·0 (484·5, 
1274·5) 
150 799·0 (246·0, 
1106·0) 
77 0·069 
Table 3: Comparison of clinical parameters between cats documented to be 621 
hypertensive and those, which remained normotensive during follow-up 622 
 623 
  624 
Variable 
(units) 
Cats remaining 
normotensive 
n 
Cats developing 
hypertension 
n 
Significance 
(P) 
Age at visit during 
15th year 
14·4 (14·1, 14·6) 146 14·3 (14·1, 14·6) 81 0·106 
Creatinine 
(µmol/L) 
151·7 (125·1, 186·4) 146 159·2 (132·4, 
201·0) 
81 0·127 
Phosphorus 
(mmol/L) 
1·28 (1·12, 1·46) 146 1·31 (1·07, 1·51) 81 0·778 
Potassium 
(mmol/L) 
4·0 (3·7, 4·3) 146 3·9 (3·6, 4·1) 81 0·02 
Weight (kg) 4·01 (3·46, 4·62) 146 4·17 (3·31, 4·68) 81 0·853 
Packed cell volume 
(%) 
36 (32, 39) 146 36 (33, 39) 79 0·845 
Urine specific 
gravity 
1·031 (1·021, 1·046) 119 1·025 (1·019, 
1·034) 
72 0·01 
Urine protein to 
creatinine ratio 
0·16 (0·11, 0·27) 40 0·16 (0·10, 0·34) 30 0·476 
Duration of follow-
up (days) 
822 (371, 1151) 81 968 (486, 1401) 81 0·138 
Diagnosis of 
hyperthyroidism 
at enrollment 
during 15th year 
- 28 - 16   
Cats diagnosed 
with 
hyperthyroidism 
during follow-up 
- 10 - 11   
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